Literature DB >> 17244662

Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.

S C B Teoh, S Sharma, A Hogan, R Lee, A V Ramanan, A D Dick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17244662      PMCID： PMC1857629          DOI： 10.1136/bjo.2006.0101477

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  19 in total

1.  Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease.

Authors:  Philip N Hawkins; Alison Bybee; Ebun Aganna; Michael F McDermott
Journal:  Arthritis Rheum       Date:  2004-08

2.  Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome.

Authors:  B Granel; J Serratrice; P Disdier; P-J Weiller
Journal:  Rheumatology (Oxford)       Date:  2005-01-25       Impact factor: 7.580

3.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

4.  Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes.

Authors:  Jérôme Feldmann; Anne-Marie Prieur; Pierre Quartier; Patrick Berquin; Stephanie Certain; Elisabetta Cortis; Dominique Teillac-Hamel; Alain Fischer; Genevieve de Saint Basile
Journal:  Am J Hum Genet       Date:  2002-05-24       Impact factor: 11.025

5.  Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel.

Authors:  Joost Frenkel; Nico M Wulffraat; Wietse Kuis
Journal:  Arthritis Rheum       Date:  2004-11

6.  The CINCA syndrome: a rare cause of uveitis in childhood.

Authors:  S A Sadiq; R M Gregson; R N Downes
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1996 Jan-Feb       Impact factor: 1.402

7.  Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis.

Authors:  J T Rosenbaum; R S Boney
Journal:  Arch Ophthalmol       Date:  1992-04

8.  Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study.

Authors:  Liisa Konttinen; Eeva Kankaanpää; Riitta Luosujärvi; Harri Blåfield; Kaisa Vuori; Markku Hakala; Vappu Rantalaiho; Elina Savolainen; Toini Uutela; Dan Nordström
Journal:  Clin Rheumatol       Date:  2006-03-22       Impact factor: 2.980

9.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.

Authors:  Virginia Pascual; Florence Allantaz; Edsel Arce; Marilynn Punaro; Jacques Banchereau
Journal:  J Exp Med       Date:  2005-04-25       Impact factor: 14.307

Review 10.  Blocking IL-1 in systemic inflammation.

Authors:  Charles A Dinarello
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307
View more
  31 in total

Review 1.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis.

Authors:  François Willermain; James T Rosenbaum; Bahram Bodaghi; Holly L Rosenzweig; Sarah Childers; Travis Behrend; Gerhild Wildner; Andrew D Dick
Journal:  Prog Retin Eye Res       Date:  2011-11-22       Impact factor: 21.198

Review 2.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

Review 3.  Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Authors:  Steven Yeh; Lisa J Faia; Robert B Nussenblatt
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

4.  Post-inflammatory retinal dystrophy in CINCA syndrome.

Authors:  Donato Rigante; Achille Stabile; Angelo Minnella; Laura Avallone; Lucia Ziccardi; Giulia Bersani; Giovanna Stifano; Adele Compagnone; Benedetto Falsini
Journal:  Rheumatol Int       Date:  2009-05-08       Impact factor: 2.631

Review 5.  Non-infectious pediatric uveitis: an update on immunomodulatory management.

Authors:  Srilakshmi M Sharma; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 6.  NLRs in immune privileged sites.

Authors:  Holly L Rosenzweig; Stephen R Planck; James T Rosenbaum
Journal:  Curr Opin Pharmacol       Date:  2011-07-29       Impact factor: 5.547

7.  The NLRP3 inflammasome is active but not essential in endotoxin-induced uveitis.

Authors:  Holly L Rosenzweig; April Woods; Jenna S Clowers; Stephen R Planck; James T Rosenbaum
Journal:  Inflamm Res       Date:  2011-11-26       Impact factor: 4.575

Review 8.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

Review 9.  Pharmacotherapy of scleritis: current paradigms and future directions.

Authors:  Robert M Beardsley; Eric B Suhler; James T Rosenbaum; Phoebe Lin
Journal:  Expert Opin Pharmacother       Date:  2013-02-21       Impact factor: 3.889

10.  Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis.

Authors:  P Trittibach; S E Barker; C A Broderick; M Natkunarajah; Y Duran; S J Robbie; J W B Bainbridge; A J Smith; G-M Sarra; A D Dick; R R Ali
Journal:  Gene Ther       Date:  2008-06-26       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.